Selskabets formål er at drive virksomhed indenfor handel og industri.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 683.2 mio. | 14 mio. | 398 mio. | 315.1 mio. | 85 | |
CVR: 66351912
Secondary names: PHARMACIA ApS, ACO ApS, KABI PHARMACIA ApS
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Hans Henrik Buur joined the board
Kjetil Hagen joined as ADM. DIR.
Lars Møller left the board
Lars Møller left as ADM. DIR.
The financial health of PFIZER ApS shows a declining trend in revenue and profit over the past few years. Revenue decreased from 2.3 billion DKK in 2022 to 683 million DKK in 2025, while profit fell significantly from 92 million DKK in 2022 to just 14 million DKK in 2025. Despite this decline, the company's equity remains relatively stable, though it has decreased from 483 million DKK in 2021 to 315 million DKK in 2025. Key concerns include shrinking profit margins and a significant drop in revenue, which may impact its competitive position within the pharmaceutical wholesale industry.
AI-generated summary
Companies in the same industry and area
companydata.dk